Highlights

  • USPTO issues a Notice of Allowance for US patent application Serial No. 17/611,158, covering the crystalline form of sofpironium bromide used in Sofdra
  • The allowed claims relate to proprietary aspects of the drug substance technology utilised in the commercial manufacture of Sofdra
  • Once issued, the patent will provide additional protection alongside existing patents covering Sofdra's commercial drug substance through to May 2040
  • Sofdra is Botanix's FDA-approved treatment for primary axillary hyperhidrosis in adults and paediatric patients aged nine years and older

Botanix Pharmaceuticals Limited (ASX:BOT) has announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering the drug substance behind Sofdra, the company's FDA-approved treatment for primary axillary hyperhidrosis. The announcement, released on 13 July 2026, adds to the company's existing intellectual property protections surrounding its commercial dermatology product.

Details of the Patent Allowance

The Notice of Allowance relates to US patent application Serial No. 17/611,158, titled 'Crystalline Form of Sofpironium Bromide and Preparation Method Thereof'. The application is directed at intellectual property covering the drug substance for Sofdra, known generically as sofpironium, which Botanix markets as a treatment for primary axillary hyperhidrosis in adults and paediatric patients aged nine years and older.

According to the announcement, the allowed claims are directed at proprietary aspects of the sofpironium drug substance technology used in the commercial manufacture of Sofdra. Upon issuance, the patent is expected to provide Botanix with additional intellectual property protection surrounding the product within the United States, its primary commercial market for the therapy.

Extension of Patent Protection

Botanix said the patent application relates to innovations associated with the sofpironium drug substance and, once issued, will supplement the protection already provided by existing issued patents covering Sofdra's commercial drug substance, which extend into May 2040. The company frames the additional filing as part of a broader effort to build out its intellectual property estate around the product as it continues its commercial launch in the United States.

Management Commentary

Botanix Chief Executive Officer Dr Howie McKibbon said strengthening the company's intellectual property estate around Sofdra remains an important strategic priority. McKibbon said the Notice of Allowance further expands the company's US patent portfolio supporting the long-term commercial opportunity for Sofdra and reinforces the company's commitment to protecting the innovations associated with the product.

About Sofdra and the Underlying Indication

Sofdra is Botanix's commercial dermatology product, approved by the US Food and Drug Administration for the treatment of primary axillary hyperhidrosis, a condition characterised by excessive underarm sweating beyond what is required for normal thermoregulation. The product's approval covers use in adults and in paediatric patients aged nine years and older, positioning Sofdra within the broader dermatology treatment landscape that Botanix has built its commercial strategy around in the United States.

Primary axillary hyperhidrosis affects a proportion of the adult population to a degree that interferes with daily activities, and treatment options historically have ranged from topical antiperspirants and prescription anticholinergic products through to more invasive procedures such as botulinum toxin injections, iontophoresis and surgery. Sofdra is administered as a topical treatment, and its approval and subsequent commercial launch reflect Botanix's strategy of building a portfolio of dermatology products addressing conditions that the company has said are often underdiagnosed and undertreated relative to their prevalence.

Intellectual Property Strategy

Patent protection is a relevant consideration for pharmaceutical companies commercialising approved therapies, as it can influence the period over which a company may be able to market a product without generic competition. Botanix's disclosure that the newly allowed patent will apply alongside existing patents extending into May 2040 indicates that the company is pursuing a layered intellectual property strategy around Sofdra, combining protection for the drug substance itself with other patents covering different aspects of the product and its use.

The company's characterisation of strengthening its intellectual property estate as an important strategic priority suggests that further patent filings and prosecutions relating to Sofdra may continue as the product's commercial life progresses. Botanix has not disclosed the number of additional patent applications pending before the USPTO or other jurisdictions in this announcement.

Company Background

Botanix Pharmaceuticals describes itself as a commercial dermatology company, reflecting its transition from a clinical-stage developer to a company generating revenue from an approved and marketed product in the United States. The company's headquarters and primary commercial operations are based in Phoenix, Arizona, reflecting the location of its main market for Sofdra. The Australian Securities Exchange listing under the code BOT provides the company's primary equity market, with the company's operations otherwise centred on its US commercial footprint.

The company's shift toward commercial-stage operations has meant that its periodic disclosures increasingly cover topics such as prescription volumes, payer coverage and intellectual property developments alongside the clinical and regulatory updates that characterised its earlier stage of development. The Notice of Allowance disclosed in this announcement falls into the intellectual property category of disclosure, distinct from sales or prescription-related updates that the company may separately report to the market.

Conclusion

The Notice of Allowance adds a further layer of patent protection to Botanix's commercial dermatology product at a stage when the company continues to build out its Sofdra launch in the United States. The extension of drug substance-related protection alongside existing patents through to 2040 forms part of the company's stated strategy of reinforcing its intellectual property estate as a component of the long-term commercial positioning of the product, with the formal issuance of the patent representing the next procedural step following this allowance.